Employees Retirement System of Texas lowered its stake in shares of Sanofi (NYSE:SNY) by 10.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 169,700 shares of the company’s stock after selling 18,800 shares during the period. Employees Retirement System of Texas’ holdings in Sanofi were worth $6,863,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. CKW Financial Group raised its position in Sanofi by 21.6% in the third quarter. CKW Financial Group now owns 2,816 shares of the company’s stock worth $108,000 after buying an additional 500 shares during the period. FNY Partners Fund LP acquired a new position in Sanofi during the fourth quarter worth $162,000. JFS Wealth Advisors LLC raised its position in Sanofi by 1.9% in the third quarter. JFS Wealth Advisors LLC now owns 4,035 shares of the company’s stock worth $154,000 after buying an additional 74 shares during the period. Jacobi Capital Management LLC raised its position in Sanofi by 31.9% in the third quarter. Jacobi Capital Management LLC now owns 4,271 shares of the company’s stock worth $164,000 after buying an additional 1,034 shares during the period. Finally, Weik Investment Services Inc. acquired a new position in Sanofi during the second quarter worth $222,000. 9.63% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) traded up 0.44% during midday trading on Thursday, hitting $43.54. The company had a trading volume of 962,489 shares. The firm has a market capitalization of $111.71 billion, a P/E ratio of 22.33 and a beta of 0.98. The company has a 50 day moving average price of $40.83 and a 200 day moving average price of $39.73. Sanofi has a 1-year low of $36.81 and a 1-year high of $44.50.

Sanofi (NYSE:SNY) last issued its earnings results on Wednesday, February 8th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.01. The company earned $8.88 billion during the quarter, compared to analyst estimates of $9.87 billion. Sanofi had a return on equity of 26.37% and a net margin of 13.66%. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post $3.05 earnings per share for the current fiscal year.

This story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at http://www.watchlistnews.com/employees-retirement-system-of-texas-sells-18800-shares-of-sanofi-sny/1120891.html.

SNY has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, February 7th. Goldman Sachs Group, Inc. (The) reaffirmed a “hold” rating on shares of Sanofi in a research note on Sunday, January 8th. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, November 29th. Leerink Swann reaffirmed an “outperform” rating on shares of Sanofi in a research note on Tuesday, January 10th. Finally, Natixis raised Sanofi from a “neutral” rating to a “buy” rating in a research note on Thursday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $65.67.

Sanofi Company Profile

Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

5 Day Chart for NYSE:SNY

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.